Use of toxicokinetics in developmental and reproductive toxicology

Developmental and Reproductive Toxicology: A Practical Approach

Volumn , Issue , 2005, Pages 571-597

  Wier, Patrick J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73649110666     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Crawford, J.S., The placenta, drugs, and the fetus, in Principles and Practice of Obstetric Anesthesia, 5th ed., Blackwell Scientific Publications, Oxford, 1984, p. 132.
2. Morriss, Jr., F.H. and Boyd, R.D.H., Placental Transport, in The Physiology of Reproduction, Knobil, E. and Neill, J., Eds., Raven Press Ltd., New York, 1988, chap. 50.
3. Rozman, K.K. and Klaassen, C.D., Absorption, distribution, and excretion of toxicants, in Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th ed., Klaassen, C.D., Ed., McGraw-Hill, New York, 2001, chap. 5.
4. Landas, G.R., et al., Placental p-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice, Reprod. Toxicol., 12, 457, 1998.
5. Goldstein, A., Aronow, L., and Kalman, S.M., Principles of Drug Action: The Basics of Pharmacology, 2nd ed., John Wiley & Sons, New York, 1974, chap 2.
6. Goldstein, A., Aronow, L., and Kalman, S.M., Principles of Drug Action: The Basics of Pharmacology, 2nd ed., John Wiley & Sons, New York, 1974, p. 821.
7. Dym, M. and Fawcett, D.W., The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium, Biol. Reprod., 3, 300, 1970.
8. Setchell, B.P., Vogimayr, J.K., and Waites, G.M.H., A blood-testis barrier restricting passage from blood lymph into rete testis fluid but not into lymph, J. Physiol., 200, 73, 1969.
9. Okumura, K., Lee, I.P., and Dixon, R.L., Permeability of selected drugs and chemicals across the blood-testis barrier of the rat, J. Pharmacol. Exp. Ther., 194, 89, 1975.
10. Hendrikse, N.H., et al., Complete in vivo reversal of p-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography, Br. J. Pharmacol., 124, 1413, 1998.
11. Hughes, C.S., et al., Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing p-glycoprotein in rats, J. Neuro-Oncology, 37, 45, 1998.
12. Choo, E.F., et al., Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metabol. Disposition, 28, 655, 2000.
13. Sieber, S.M. and Fabro, S., Identification of drugs in the preimplantation blastocyst and in the plasma, uterine secretion and urine of the pregnant rabbit, J. Pharmacol. Exp. Ther., 176, 65, 1971.
14. McLachlan, J.A., et al., Accumulation of nicotine in the uterine fluid of the six-day pregnant rabbit, Fertil. Steril., 27, 1204, 1967.
15. Beck, F., Comparative placental morphology and function, in Developmental Toxicology, Kimmel, C.A. and Buelke-Sam, J., Eds., Raven Press, New York, 1981, p. 35.
16. Amoroso, E.C., Placentation, in Marshall's Physiology of Reproduction, 3rd ed., Parkes, A.S., Ed., Longmans, London, 1952, Vol. II, chap. 15.
17. Mirkin, B.L., Perinatal pharmacology: placental transfer, fetal localization, and neonatal disposition of drugs, Anesthesiology, 43, 156, 1975.
18. Williams, R.T., Detoxification Mechanisms, 2nd ed., Wiley, New York, 1971.
19. Parkinson, A., Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th Ed., Klaassen, C.D., Ed., McGraw-Hill, New York, 2001, chap. 6.
20. Juchau, M.R., Mechanisms of drug biotransformation reactions in the placenta, Fed. Proc., 31, 48, 1972.
21. Juchau, M.R., Drug biotransformation in the placenta, Pharmacol. Ther., 8, 501, 1980.
22. Heinrichs, W.L. and Juchau, M.R., Extrahepatic drug metabolism: the gonads, in Extrahepatic Metabolism of Drugs and Other Foreign Compounds, Gram, T.E., Ed., SP Medical and Scientific Books, New York, 1980, p. 313.
23. Ishimura, K., et al., Ultrastructural and immunohistochemical studies on steroid-secreting cells of testis and ovary of normal and 3-methylcholanthrene-treated mice, Cell & Tissue Research, 245, 681, 1986.
24. Batt, A.M., et al., Enzyme induction by drugs and toxins, Clinica Chimica Acta, 209, 109, 1992.
25. Krishna, D.R. and Klotz, U., Extrahepatic metabolism of drugs in humans, Clin. Pharmacokinet., 26, 144, 1994.
26. Slikker, W. and Miller, R.K., Placental metabolism and transfer: role in developmental toxicology, in Developmental Toxicology, 2nd ed., Kimmel, C.A. and Buelke-Sam, J., Eds., Raven Press, New York, 1994, p. 245.
27. Ring, J.A., et al., Fetal hepatic drug elimination, Pharmacol. Ther., 84, 429, 1999.
28. Thomas, J.A., Curto, K.A., and Thomas, M.J., MEHP/DEHP gonadal toxicity and effects on rodent accessory sex organs, Environ. Health Perspect., 45, 85, 1982.
29. Foster, P.M.D., et al., Testicular toxicity of 2-methoxyacetaldehyde, a possible metabolite of ethylene glycol monomethyl ether in the rat, Toxicol. Lett., 32, 73, 1986.
30. Boekelheide, K., 2,5-Hexanedione alters microtubule assembly: I. Testicular atrophy, not nervous system toxicity, correlates with enhanced tubulin polymerization, Toxicol. Appl. Pharmacol., 88, 370, 1987.
31. Gerber, N. and Lynn, R.K., Excretion of methadone in semen from methadone addicts; comparison with blood levels, Life Sci., 19, 787, 1976.
32. Swanson, B.N., et al., Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit, J. Pharmacol. Exp. Ther., 206, 507, 1978.
33. Taylor, S.M., et al., The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit, J. Pharmacol. Exp. Ther., 213, 289, 1980.
34. Beach, C.A., Bianchine, J.R., and Gerber, N., The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen, J. Clin. Pharmacol., 24, 120, 1984.
35. Beach, C.A., et al., Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit, J. Pharmacol. Exp. Ther., 233, 18, 1985.
36. Kershaw, R.A., et al., Excretion of acetaminophen in semen of men: comparison with concentration in plasma, J. Am. Coll. Toxicol., 1, 113, 1982.
37. Kershaw, R.A., et al., Disposition of aspirin and its metabolites in the semen of man, J. Clin. Pharmacol., 27, 304, 1987.
38. Swanson, B.N., et al., Excretion of valproic acid into semen of rabbits and man, Epilepsia, 19, 541, 1978.
39. Lundquist, F., Aspects of biochemistry of human semen, Acta Physiol. Scand., 19, 66, 1949.
40. White, M.A., Changes in pH of expressed prostatic secretion during the course of prostatitis, Proc. R. Soc. Med., 68, 511, 1975.
41. Winningham, D.G., Nemoy, N.J., and Stamey, T.A., Diffusion of antibiotics from plasma into prostatic fluid, Nature, 219, 139, 1968.
42. Winningham, D.G. and Stamey, T.A., Diffusion of sulfonamides from plasma into prostatic fluid, J. Urol., 104, 559, 1970.
43. Paladine, W.J., et al., Possible sensitivity to vinblastine in prostatic fluid. N. Engl. J. Med., 292, 52, 1975.
44. Lutwak-Mann, C., Schmid, K., and Keberle, H., Observations of the progeny of thalidomide treated male rabbits, Br. Med. J., 1, 1090, 1964.
45. Anderson, P.O., Drug use during breast feeding, Clin. Pharm., 10, 594, 1991.
46. Oo, C.Y., et al., Active transport of cimetidine into human milk, Clin. Pharmacol. Ther., 58, 548, 1995.
47. Ito S. and Koren G., A novel index for expressing exposure of the infant to drug in breast milk, Br. J. Clin. Pharmacol., 38, 99, 1994.
48. Atkinson, H.C., Begg, E.J., and Darlow, B.A., Drugs in human milk: clinical pharmacokinetic considerations, Clin. Pharmacokinet., 14, 217, 1988.
49. Ito, S., Drug therapy for breast-feeding women, New Engl. J. Med., 343, 118, 2000.
50. Matsuda, S., Transfer of antibiotics into maternal milk, Biol. Res. Pregnancy, 5, 57, 1984.
51. Mattison, D.R., Physiological variations in pharmacokinetics during pregnancy, in Drug and Chemical Action in Pregnancy, Fabro, S. and Scialli, A.R., Eds., Dekker, New York, 1986, p. 37.
52. Mattison, D.R., Blann, E., and Malek, A., Physiological alterations during pregnancy: impact on toxicokinetics, Fund. Appl. Toxicol., 16, 215, 1991.
53. Krauer, B., Physiological changes and drug disposition during pregnancy, in Pharmacokinetics in Teratogenesis, Vol. 1, Nau, H. and Scott, W.J., Eds., CRC Press, Boca Raton, 1987, chap. 1.
54. Hytten, F.E. and Thomson, A.M., Maternal physiological adjustments, in Biology of Gestation, Vol. 1, The Maternal Organism, Assali, N.S., Ed., Academic Press, New York, 1968, chap. 8.
55. Johnson, R.L., et al., Cardiac output distribution and uteroplacental blood flow in the pregnant rabbit: a comparative study, Am. J. Obstet. Gynecol., 151, 682, 1985.
56. Koldovsky, O., Digestion and absorption, in Perinatal Physiology, Stave, U., Ed., Plenum Medical Book Company, New York, 1978, chap. 15.
57. Calabrese, E.J., Age and Susceptibility to Toxic Substances, John Wiley & Sons, New York, 1986.
58. Znamenacek, K. and Pibylová, H., The effect of glucose and insulin administration on the blood glucose levels of the newborn, Cesk. Pediatr. (Prague), 18, 104, 1963.
59. Angus, G.E. and Thurlbeck, W.M., Number of alveoli in the human lung, J. Appl. Physiol., 32, 483, 1972.
60. Besunder, J.B., Reed, M.D., and Blumer, J.L., Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part I), Clin. Pharmacokinet., 14, 189, 1988.
61. Kurz, H., Michels, H., and Stickel, H.H., Differences in the binding of drugs to plasma proteins from newborn and adult man (part II), Eur. J. Clin. Pharmacol., 11, 469, 1977.
62. Himwich, W.A., Physiology and pharmacology of the central nervous system, in Perinatal Physiology, Stave, U., Ed., Plenum Medical Book Company, New York, 1978, chap. 29.
63. Neims, A.H., et al., Developmental aspects of the hepatic cytochrome P-450 monooxygenase system, Ann. Rev. Pharmacol. Toxicol., 16, 427, 1976.
64. Klinger, W., Biotransformation of drugs and other xenobiotics during postnatal development, Pharmacol. Ther., 16, 377, 1982.
65. Juchau, M.R., Fetal and neonatal drug biotransformation, in Drug Toxicity and Metabolism in Pediatrics, Kacew, S., Ed., CRC Press, Boca Raton, FL, 1990, p.15.
66. Klaassen, C.D., Immaturity of the newborn rat's hepatic excretory function for ouabain, J. Pharmacol. Exp. Ther., 183, 520, 1972.
67. Ballatori, N. and Clarkson, T.W., Developmental changes in the biliary excretion of methylmercury and glutathione, Science, 216, 61, 1982.
68. Fetterman, G.H., et al., The growth and maturation of human glomeruli and proximal convolutions from term to adulthood, J. Pediat., 35, 601, 1965.
69. Gomez, R.A., et al., The maturing kidney: development and susceptibility, Renal Failure, 21, 283, 1999.
70. Morselli, P.L. and Provei, V., Placental transfer of pethidine and norpethidine and their pharmacoki-netics in the newborn, Eur. J. Clin. Pharmacol., 18, 25, 1980.
71. Rajchgot, P. and MacLeod, S., Perinatal pharmacology, in Developmental Pharmacology, MacLeod, S., Okey, A.B., and Spielberg, S.P., Eds., Alan R. Liss, New York, 1983, p. 14.
72. Kauffman, R.E., The role of chloramphenicol in pediatric therapy, in Developmental Pharmacology, MacLeod, S., Okey, A.B., and Spielberg, S.P., Eds., Alan R. Liss, New York, 1983, p. 315.
73. Goldstein, A., Aronow, L., and Kalman, S.M., Principles of Drug Action: The Basics of Pharmacology, 2nd Ed., John Wiley & Sons, New York, 1974, pp. 291.
74. Ambrose, P.J., Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate, Clin. Pharmacokinet., 9, 222, 1984.
75. Aranda, J.V., et al., Pharmacokinetic aspects of theophylline in premature newborns, New Engl. J. Med., 295, 413, 1976.
76. Boutroy, M.J., et al., Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant, J. Pediat., 94, 996, 1979.
77. Aranda, J.V., Turmen, T., and Sasyniuk, B.I., Pharmacokinetics of diuretics and methylxanthines in the neonate, Eur. J. Clin. Pharmacol., 18, 55, 1980.
78. Busto, U., Bendayan, R., and Sellers, E.M., Clinical pharmacokinetics of non-opiate abused drugs, Clin. Pharmacokinet., 16, 1, 1989.
79. Wagner, J.G., Do you need a pharmacokinetic model and, if so, which one? J. Pharmacokinet. Biopharm., 3, 457, 1975.
80. Rowland, M. and Tozer, T.N., Clinical Pharmacokinetics: Concepts and Applications, Lea and Febiger, Philadelphia, 1980.
81. Gibaldi, M. and Perrier, D., Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982.
82. Himmelstein, K.J. and Lutz, R.J., A review of the applications of physiologically based pharmacok-inetic modeling, J. Pharmacokinet. Biopharm., 7, 127, 1979.
83. Gerlowski, L.E. and Jain, R.K., Physiologically based pharmacokinetic modeling: principles and applications, J. Pharm. Sci., 72, 1103, 1983.
84. Conolly, R.B. and Andersen, M.E., Biologically based pharmacodynamic models: tools for toxico-logical research and risk assessment, Annu. Rev. Pharmacol. Toxicol., 31, 503, 1991.
85. Krishnan, K. and Andersen, M.E., Physiologically based pharmacokinetic modeling in toxicology, in Principles and Methods of Toxicology, 4th ed., Hayes, A.W., Ed., Taylor and Francis, Philadelphia, 2001, chap. 5.
86. Olanoff, L.S. and Anderson, J.M., Controlled release of tetracycline - III: A physiological pharmacokinetic model of the pregnant rat, J. Pharmacokinet. Biopharm., 8, 599, 1980.
87. Gabrielsson, J.L. and Paalzow, L.K., A physiological pharmacokinetic model for morphine disposition in the pregnant rat, J. Pharmacokinet. Biopharm., 11, 147, 1983.
88. Gabrielsson, J.L., Paalzow, L.K., and Nordstrom, L., A physiologically based pharmacokinetic model for theophylline disposition in the pregnant and nonpregnant rat, J. Pharmacokinet. Biopharm., 12, 149, 1984.
89. Gabrielsson, J.L., et al., Analysis of methadone disposition in the pregnant rat by means of a physiological flow model, J. Pharmacokinet. Biopharm., 13, 355, 1985.
90. Gabrielsson, J.L., et al., Analysis of pethidine disposition in the pregnant rat by means of a physiological flow model, J. Pharmacokinet. Biopharm., 14, 381, 1986.
91. Fisher, J.W., et al., Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid, Toxicol. Appl. Pharmacol., 99, 395, 1989.
92. O'Flaherty, E.J., et al., A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid, Toxicol. Appl. Pharmacol., 112, 245, 1992.
93. Clarke, D.O., et al., Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model, Toxicol. Appl. Pharmacol., 121, 239, 1993.
94. Terry, K.K., et al., Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse, Toxicol. Appl. Pharmacol., 132, 103, 1995.
95. Hays, S.M., et al., Development of a physiologically based pharmacokinetic model of 2-methoxyeth-anol and 2-methoxyacetic acid disposition in pregnant rats, Toxicol. Appl. Pharmacol., 163, 67, 2000.
96. Gargas, M.L., et al., A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human, Toxicol. Appl. Pharmacol., 165, 53, 2000.
97. Gabrielsson, J.L. and Larsson, K.S., Proposals for improving risk assessment in reproductive toxicology, Pharmacol. Toxicol., 66, 10, 1990.
98. Welsch, F., Blumenthal, G.M., and Conolly, R.B., Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments, Toxicol. Letters, 82-83, 539, 1995.
99. Luecke, R.H., et al., A physiologically based pharmacokinetic computer model for human pregnancy, Teratology, 49, 90, 1994.
100. Luecke, R.H., et al., A computer model and program for xenobiotic disposition during pregnancy, Computer Methods Programs Biomed., 53, 201, 1997.
101. Diehl, K.-H., et al., A good practice guide to the administration of substances and removal of blood, including routes and volumes, J. Appl. Toxicol., 21, 15, 2001.
102. Smith Kline and French Laboratories, Philadelphia, Small Animal Milking Apparatus, U.S. Patent 3,580,220.
103. ICH Guideline S5A: Reproductive Toxicology: Detection of Toxicity to Reproduction for Medicinal Products (CPMP/ICH/386/95).
104. ICH Guideline S3A: Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (CPMP/ICH/384/95).
105. Kochar, D.M., Kraft, J., and Nau, H., Teratogenicity and disposition of various retinoids in vivo and in vitro, in Pharmacokinetics in Teratogenesis, Vol. 2, Nau, H. and Scott, W.J., Eds., CRC Press, Boca Raton, 1987, chap. 16.
106. Agnish, N.D., Rusin, G., and DiNardo, B., Taurine failed to protect against the embryotoxic effects of isotretinoin in the rat, Fund. Appl. Toxicol., 15, 249, 1990.
107. Collins, M.D., et al., Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administration in rats, Toxicol. Appl. Pharmacol., 127, 132, 1994.
108. Eckhoff, C., et al., Teratogenicity and transplacental pharmacokinetics of 13-cis-retinoic acid in rabbits, Toxicol. Appl. Pharmacol., 125, 34, 1994.
109. Hummler, H., Korte, R., and Hendrickx, A.G., Induction of malformations in the cynomolgus monkey with 13-cis retinoic acid, Teratology, 42, 263, 1990.
110. Hummler, H., Hendrickx, A.G., and Nau, H., Maternal toxicokinetics, metabolism, and embryo exposure following a teratogenic dosing regimen with 13-cis-retinoic acid (Isotretinoin) in the cyno-molgus monkey, Teratology, 50, 184, 1994.
111. Creech Kraft, J., et al., Teratogenicity and placental transfer of all-trans-13-cis, 4-oxo-all-trans- and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice, Toxicol. Appl. Pharmacol., 100, 162, 1989.
112. Kalin, J.R., Wells, J., and Hill, D.L., Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl) retinamide in mice after oral doses, Drug Metab. Dispos., 10, 391, 1982.
113. Shelly, R.S., et al., Blood level studies of all-trans- and 13-cis-retinoic acid in rats using different formulations, J. Pharm. Sci., 71, 904, 1982.
114. Kamm, J.J., Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids, J. Am. Acad. Dermatol., 6, 652, 1982.
115. Nau, H., Species differences in pharmacokinetics, drug metabolism, and teratogenesis, in Pharmaco-kinetics in Teratogenesis, Vol. 1, Nau, H. and Scott, W.J., Eds., CRC Press, Boca Raton, 1987, chap. 6.
116. Nau, H., Teratogenic valproic acid concentrations: infusion by implanted minipumps vs. conventional injection regimen in the mouse, Toxicol. Appl. Pharmacol., 80, 243, 1985.
117. Meijer, J.W.A. and Hessing-Brand, L., Determination of lower fatty acid, particularly the antiepileptic dipropylacetic acid, in biological material by means of microdiffusion and gas chromatography, Clinica Chimica Acta, 43, 215, 1973.
118. Nau, H. and Löscher, W., Valproic acid and metabolites: pharmacological and toxicological studies, Epilepsia, 25 (Suppl 1), S14, 1984.
119. Robert, E. and Guibaud, P., Maternal valproic acid and congenital neural tube defects, Lancet, 2, 937, 1982.
120. Robert, E. and Rosa, F., Valproate and birth defects, Lancet, 2, 1142, 1983.
121. Lindhout, D. and Meinardi, H., Spina bifida and in-utero exposure to valproate, Lancet, 2, 396, 1984.
122. Mirkes, P.E., Cyclophosphamide teratogenesis: a review, Teratogenesis, Carcinogenesis, Mutagenesis, 5, 75, 1985.
123. Reiners, J., et al., Teratogenesis and pharmacokinetics of cyclophosphamide after drug infusion as compared to injection in the mouse during day 10 of gestation, in Pharmacokinetics in Teratogenesis, Vol. 2, Nau, H. and Scott, W.J., Eds., CRC Press, Boca Raton, 1987, chap. 4.
124. Nau, H., et al., Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives, Mutation Res., 95, 105, 1982.
125. Juma, F.D., Rogers, H.J., and Trounce, J.R., The pharmacokinetics of cyclophosphamide, phosphora-mide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclo-phosphamide therapy, Br. J. Clin. Pharmacol., 10, 327, 1980.
126. Nau, H., Species differences in pharmacokinetics and drug teratogenesis, Environ. Health Perspect., 70, 113, 1986.
127. Nau, H., Pharmacokinetic considerations in the design and interpretation of developmental toxicity studies, Fund. Appl. Toxicol., 16, 219, 1991.
128. Terry, K.K., et al., Developmental phase alters dosimetry-teratogenicity relationship for 2-methoxy-ethanol in CD-1 mice, Teratology, 49, 218, 1994.
129. Clarke, D.O., Duignan, J.M., and Welsch, F., 2-Methoxyacetic acid dosimetry-teratogenicity relationships in CD-1 mice exposed to 2-methoxyethanol, Toxicol. Appl. Pharmacol., 114, 77, 1992.
130. Sleet, R.B., et al., Developmental phase specificity and dose-response effects of 2-methoxyethanol teratogenicity in rats, Fund. Appl. Toxicol., 29, 131, 1996.
131. Hansen, D.K., et al., Pharmacokinetic considerations of dexamethasone-induced developmental toxicity in rats, Toxicological Sciences, 48, 230, 1999.
132. Hays, S.M., et al., Development of a physiologically based pharmacokinetic model of 2-methoxyeth-anol and 2-methoxyacetic acid disposition in pregnant rats, Toxicol. Appl. Pharmacol., 163, 67, 2000.